سعر فانجيليميت 200مجم 10 اقراص 2025

Voriconazole 200 mg film-coated tablets, pack of 10; a triazole antifungal for invasive fungal infections.

• Invasive aspergillosisPopulation: Adults and paediatric patients 2 years and olderDailyMed (U.S. National Library of Medicine)
• Candidaemia in non-neutropenic patients and disseminated Candida infections of skin, abdomen, kidney, bladder wall and woundsPopulation: Adults and paediatric patients 2 years and olderDailyMed (U.S. National Library of Medicine)
• Oesophageal candidiasisPopulation: Adults and paediatric patients 2 years and olderDailyMed (U.S. National Library of Medicine)

• Most common: visual disturbances (about 18.7%), fever, nausea, rash, vomiting, chills, headache, liver test abnormalities, tachycardia and hallucinations.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Hypersensitivity to voriconazole or excipients.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Coadministration with CYP3A4 substrates such as pimozide, quinidine and ivabradine (QT prolongation), ergot alkaloids, sirolimus, and with rifampin, carbamazepine, long-acting barbiturates, high-dose ritonavir, rifabutin, efavirenz 400 mg every 24 hours or higher, or St John's Wort, among others listed in the label.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Serious hepatic reactions have occurred; monitor liver function tests at the start of and during therapy.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• QT prolongation and torsades de pointes have been reported; correct potassium, magnesium and calcium before starting.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• Visual disturbances are common; monitor visual function if treatment continues beyond 28 days.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A4, CYP2C9 and CYP2C19 substrates, inhibitors and inducersVoriconazole is metabolised by and inhibits CYP2C19, CYP2C9 and CYP3A4; many combinations are contraindicated or need dose adjustment and monitoring.DailyMed (U.S. National Library of Medicine)

• Voriconazole can cause fetal harm when given to a pregnant woman; advise of the potential risk and use effective contraception during treatment.International label, same formulation · DailyMed (U.S. National Library of Medicine)
• No data on the presence of voriconazole in human milk or effects on the breastfed infant.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Voriconazole: Inhibits fungal cytochrome P450-dependent 14-alpha-lanosterol demethylation, blocking ergosterol synthesis.